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Abstract
Corepressors are large proteins that facilitate transcriptional repression through recruitment of
histone-modifying enzymes. Two major corepressors, SMRT (silencing mediator for retinoid and
thyroid hormone receptors) and N-CoR (nuclear receptor corepressor), have been shown to
mediate repression associated with nuclear receptors and a myriad of other transcription factors.
This review will focus on recent studies on these proteins, including newly discovered physiological
roles of the corepressors, their modes of regulation, their roles in antiestrogen-resistant breast
cancer and their functions during the cell cycle.
SMRT and N-CoR are transcriptional 
corepressors
Control of transcription is mediated by many signaling
pathways, including small, non-protein steroids. Steroids
control transcription by binding to nuclear receptors
(NRs) which in turn modulate transcription of target
genes. Studies of nuclear receptor signaling has led to the
elucidation of basic mechanisms of transcriptional activa-
tion, repression and identification of the specific protein
families that control these processes (coactivators and
corepressors, [1,2]). In particular, corepressors mediate
the active repression of transcription through recruitment
of enzymes to post-translationally modify histone tails.
Furthermore, corepressors themselves are subject to regu-
lated control of activity, localization and stability through
various intercellular pathways. Corepressors are critical
for the treatment of certain breast cancers and may also
play important roles in the regulation of mitosis.
The first nuclear receptor corepressors identified, SMRT
and N-CoR, were isolated in yeast 2-hybrid screens as
interacting partners of retinoid X or thyroid hormone
receptor (RXR, TR) [3-7]. SMRT and N-CoR share approx-
imately 45% amino acid sequence identity [8] and both
are subject to extensive alternative mRNA splicing, gener-
ating multiple isoforms [9]. These two corepressors likely
share some similar functions while exerting other, distinct
influences within cells and organisms. While many inter-
action partners are shared between the two corepressors,
other interaction partners are specific to each corepressor.
Corepressor domains and stable interacting partners
The corepressors SMRT and N-CoR share similar domain
organizations and are believed to be paralogs [8]. Both
proteins contain multiple repression domains (RDs),
Swi3/Ada2/N-CoR/TFIIID (SANT) motifs [10] and
nuclear receptor interaction domains (NRIDs). SANT
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motifs in corepressors have been shown to be histone
binding modules [10,11], although specific mechanisms
underlying this are unclear. SMRT contains two NRIDs,
while N-CoR contains three NRIDs. The NRIDs in each
can be removed by alternative splicing. The RDs likely
serve as binding platforms for the various silencing
enzymes recruited to repress gene promoters, including
the histone deacetylases (HDACs). Thus, both SMRT and
N-CoR are part of larger complexes. These corepressor
complexes can be considered to be large docking surfaces
to tether repression machinery to transcription factors.
Both SMRT and N-CoR have been subjected to extensive
biochemical purification to identify core components of
their respective complexes. Both complexes contain the
same core associated factors, including HDAC3, GPS2 (G
protein pathway suppressor 2; X. Cheng and H.Y. Kao,
unpublished data) and the transducin β-like factors, TBL1
and TBLR1 [12-16]. These four proteins consistently co-
purify together with both SMRT and N-CoR. Interaction of
HDAC3 with either the SMRT or the N-CoR complex is
thought to promote deacetylase activity on histones
[10,13,17]. Other HDACs also interact with SMRT or N-
CoR complexes, including class II HDACs 4, 5 and 7 [17-
20] and class I HDACs 1 and 2 (through the corepressor
mSin3 (mammalian switch independent 3 protein)) [21-
23], but their roles in SMRT- and N-CoR-dependent gene
repression is unclear. In order to form an active SMRT-
HDAC3 complex, association with the TRiC-1 (TCP1 ring
complex) chaperone is required [24]. This process is ATP-
dependent and TRiC-1 dissociates from SMRT-HDAC3
following complex formation. Although this requirement
has only been demonstrated for SMRT complex forma-
tion, it is likely that a similar pathway exists for N-CoR
complex formation.
Corepressor-mediated repression
One major function of SMRT and N-CoR is the repression
of gene transcription. This function is modulated in part
through deacetylation of lysines on histone tails by his-
tone deacetylases contained in large corepressor com-
plexes. Deacetylated histones may serve as preferred
binding sites for corepressor complexes in what has been
described as a "feed-forward mechanism" [11]. Current
models indicate that corepressor complexes initially rec-
ognize acetylated chromatin and deacetylates the histone
tails. These complexes may then show increased affinity
for the deacetylated chromatin, thus enhancing gene
repression by increased association. HDAC3 is hypothe-
sized to be the primary histone deacetylase in SMRT/N-
CoR complexes. A novel domain termed the deacetylase
activating domain (DAD) in both SMRT and N-CoR
(located between the two SANT domains) has been
shown to promote both the enzymatic activity and bind-
ing of HDAC3 [10]. HDAC3 alone targets acetylated
lysines on histone H2A and lysines K5 and K12 of H4 in
vitro [25]; another study reported N-CoR/HDAC3 com-
plexes were specific for H3 in vitro [26]. This suggests that
corepressor complexes direct the substrate specificity of
HDAC3. Extending these studies into mammalian cells, it
was shown that SMRT/HDAC3-mediated deacetylation
was specific for H4 on the RARγ2 gene [27]. Further work
may elucidate the specific roles of the various HDACs in
corepressor complexes and identify actual target lysine
residues on histone tails.
SMRT and N-CoR have non-overlapping physiological 
functions
SMRT knockout mice (SMRT -/- mice) have recently been
described [28,29]. This gene disruption is an embryonic
lethal at approximately embryonic day 16.5 (E16.5) due
mainly to defects in cardiogenesis [29]. Specifically, aber-
rations were observed in ventricular septation and hypo-
plasia of the ventricular chambers of the heart. The
mechanism has been partially delineated as being fork-
head box protein 1 (FOXP1) dependent. FOXP1 -/-, SMRT
-/- and SMRT +/-/FOXP1 +/- embryos all show similar
phenotypes. SMRT and FOXP1 interact in embryonic
hearts and colocalize to chromatin to repress target gene
transcription [29]. It was further demonstrated that re-
expression of α-myosin heavy chain promoter-driven
SMRT rescued the SMRT -/- heart defects and the animals
survived to birth [28]. However, these rescued animals
exhibited significant defects in forebrain development,
including major deficiencies in the proportional volumes
of dorsal and ventral telencephalon regions. Isolated neu-
ral progenitor cells from SMRT -/- animals were prone to
differentiate into both neurons and glial cells, indicating
that SMRT prevents neuronal stem cell self-renewal. This
differentiation effect was shown to be both RAR- and
retinoic acid-dependent with the underlying mechanism
being repression of the JMJD3 histone demethylase. The
absence of SMRT activates JMJD3 which in turn activates
genes required for neuronal differentiation by demethyl-
ating H3K27 tri-methylation [28].
Similar to SMRT -/- mice, knockout of the N-CoR gene in
mice (N-CoR -/- mice) is also an embryonic lethal [30].
However, N-CoR deficient mice typically die by E15.5,
one day earlier than SMRT -/- embryos. Observed pheno-
types include smaller livers, smaller overall size and ane-
mia due to erythropoietic defects. N-CoR -/- embryos also
showed defects in T cell development and lower thymo-
cyte counts. Other defects included major aberrations in
nervous system development which was hypothesized to
be due to increased neural differentiation. This is similar
to SMRT -/- animals, although the underlying mecha-
nisms were not studied in detail. Fibroblasts derived from
N-CoR -/- animals displayed altered repression of NR-
driven luciferase reporters in transfection assays. Together,Cell Division 2009, 4:7 http://www.celldiv.com/content/4/1/7
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these data indicate that N-CoR controls a plethora of
important developmental pathways some of which are
independent of SMRT.
Recent work from multiple groups has identified several
important physiological roles for SMRT and N-CoR using
mutational approaches. Two groups, one deleting the
NRIDs of N-CoR [31] and the other mutating the NRIDs
of SMRT [32], showed that both corepressors are critical
for thyroid control of metabolism. Furthermore, SMRT
NRID mutant animals were obese due to spontaneous
adipogenesis. N-CoR mutant mice that cannot interact
with HDAC3 are lean and have abnormal circadian
rhythms [33], indicating that corepressor-mediated
repression is critical for both metabolism and normal cir-
cadian activities. Together, these animal studies indicate
that SMRT and N-CoR are critical for normal mammalian
physiology.
Post-translational modifications of corepressors
It is well-established that SMRT and N-CoR repress tran-
scription. Until recently, it was assumed that SMRT and N-
CoR had overlapping cellular functions since they share
both sequence and functional similarity. However, recent
work has demonstrated that these two proteins, while
sharing some functions, are regulated in unique ways,
including distinct patterns of alternative splicing
(reviewed in [9]) and post-translational modifications.
This idea is supported by the mouse models mentioned
previously, indicating that each corepressor is individu-
ally required for distinct pathways critical for normal
mammalian development.
Phosphorylation of corepressors
Several studies investigating the transcriptional regulation
of NF-κB-controlled genes have identified a role for SMRT
repression and a mechanism that relieves SMRT-mediated
repression [34,35]. SMRT has been shown to repress genes
such as ciap-2 and IL-8, which are NF-κB target genes. Ini-
tial studies revealed that the IKKα kinase is recruited to
chromatin in response to various stimuli where it phos-
phorylates SMRT at Ser2410. This phosphorylated site
serves as a recognition motif for the 14-3-3ε signaling pro-
tein, which exports SMRT out of the nucleus leading to
proteasome-mediated degradation. This translocation
results in activation of the ciap-2 and IL-8 genes [34].
In addition to IKKα, SMRT is subject to phosphorylation
by other kinases, including casein kinase 2 (CK2), epider-
mal growth factor receptor (EGFR), mitogen-activated
protein kinase-related pathways (MAPK) and calmodulin-
dependent protein kinase IV (CamKIV). Due to a shift in
the electrophoretic mobility of SMRT in response to trans-
forming growth factor β (TGFβ) treatment in several cell
lines, various kinase pathways were investigated to iden-
tify the source of the shift [36]. CK2, a downstream effec-
tor of TGFβ, was found to be the relevant SMRT-targeting
kinase. CK2 phosphorylates SMRT on Ser1492 which sta-
bilizes the association between SMRT and NRs and thus
enhances repression.
When cells were cotransfected with v-erbB, a constitu-
tively active form of the EGFR (epidermal growth factor
receptor), TR-mediated SMRT-dependent repression was
abolished with little effect on TR-mediated gene activa-
tion [37]. This was due to a loss of interaction between
SMRT and TR. It is likely that v-erbB phosphorylates mul-
tiple sites on SMRT, as these derepression effects were
manifested over the whole protein rather than just the NR
boxes that mediate TR binding.
Several studies have identified MAPK signaling as inhibi-
tory to SMRT-mediated repression. The MAPK MEKK1
was shown to phosphorylate SMRT and induce nuclear
export of SMRT, thus de-repressing target genes [38]. Fur-
ther studies established that this signaling was unique to
SMRT, as N-CoR remained localized in the nucleus in
response to MEKK1 expression [39]. A similar mechanism
was shown for SMRT phosphorylation by CamKIV in
response to cell stimulation, such as Ca2+ release in neu-
rons [40]. It was further demonstrated that protein phos-
phatase 1 could dephosphorylate SMRT to induce nuclear
retention and promote repression of target genes [40].
SMRT has been shown to co-purify with DNA protein
kinase (DNA-PK) and other DNA repair complex compo-
nents such as Ku70 and Ku80 [41]. Interestingly, Ku70
was shown to recruit SMRT to DNA to repress transcrip-
tion and this appears to be specific for SMRT and not N-
CoR. Furthermore, knockdown of SMRT, but not N-CoR
sensitized cells to DNA damage, indicating a potential
role for SMRT in DNA damage repair. It is not clear
whether DNA-PK phosphorylates SMRT in this pathway.
Few N-CoR-targeting kinases have been identified. Using
biochemical methods, DNA-PK was identified in the N-
CoR complex and was shown to phosphorylate HDAC3
which inhibits N-CoR-dependent repression [42]. Addi-
tionally, Ku70, Ku86 and PARP1 (poly(ADP-ribose)
polymerase 1) were also identified in the complex,
although not examined in detail. This report, along with
the observation that SMRT, but not N-CoR, is required for
Ku70-dependent DNA repair [41], suggests that N-CoR
either sequesters DNA repair proteins or that complexes
containing N-CoR and Ku70 have an as-yet undetermined
function. Exploration of this mechanism may reveal fur-
ther differences between SMRT and N-CoR signaling.
Degradation of corepressors
Several studies have explored the mechanisms controlling
the stability of N-CoR and SMRT. Using the N-terminal
region of N-CoR as bait in a yeast 2-hybrid screen, the E3Cell Division 2009, 4:7 http://www.celldiv.com/content/4/1/7
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ubiquitin ligase mSiah2 was identified as an N-CoR-inter-
acting protein [43]. mSiah2 was shown to target N-CoR
for proteasomal degradation in addition to reversing N-
CoR-mediated transcriptional repression (Figure 1). This
effect was specific to N-CoR, as no degradation of SMRT
was observed. In another study it was observed that estro-
gen treatment decreased N-CoR protein levels, but not N-
CoR mRNA [44]. Estrogen treatment up-regulates both
mSiah2 mRNA and protein levels likely resulting in degra-
dation of N-CoR. The degradation could be reversed by
treatment with the proteasome inhibitor MG132 or
siRNA targeting mSiah2. This mechanism was identified
as a novel pathway to activate ER-regulated genes such as
24-hydroxylase.
We have recently identified a novel pathway targeting
SMRT for degradation [45]. The peptidyl-prolyl isomerase
Pin1 was shown to be a SMRT-interacting protein by yeast
2-hybrid screening. Pin1 binds substrates at phosphor-
ylated serine-proline or threonine-proline dipeptide
motifs (pS-P or pT-P) and isomerizes proline motifs from
cis  to trans  (or trans  to cis). We found that the cyclin-
dependent kinase Cdk2 phosphorylates SMRT to generate
Pin1 binding sites. Upon binding these sites, Pin1 likely
induces conformational changes in SMRT via proline
isomerization. Together, Cdk2 and Pin1 promote degra-
dation of SMRT (Figure 1). Neither Cdk2 nor Pin1 coim-
munoprecipitated N-CoR, indicating that this pathway is
specific for SMRT, as the Siah2 pathway is for N-CoR. Fur-
thermore, both Cdk2 activity and Pin1 levels are posi-
tively regulated by the tyrosine kinase receptor Her2/neu/
ErbB2. Together, our results indicate that the stability of a
corepressor protein can be regulated through a membrane
receptor-dependent pathway; this pathway also has
important implications in tamoxifen-resistant breast can-
cers, as discussed below.
Degradation of pathways for SMRT and N-CoR Figure 1
Degradation of pathways for SMRT and N-CoR. SMRT and N-CoR are subject to unique degradation pathways. Estro-
gen (E2) increases mRNA levels of the E3 ubiquitin ligase mSiah2. mSiah2 targets N-CoR for degradation by the proteasome. 
SMRT is degraded by a distinct pathway. SMRT is phosphorylated by Cyclin-dependent kinase 2 (Cdk2) and potentially other 
kinases. Phosphorylated SMRT then serves as a substrate for the peptidyl-prolyl isomerase Pin1 which alters the conformation 
of its substrate. Both Pin1 levels and Cdk activity are increased by the oncoprotein ErbB2; furthermore, Pin1 can increase 
ErbB2 activity. SMRT is then degraded, likely by subsequent ubiquitination and targeting to the proteasome. Loss of corepres-
sors likely increases transcription of target genes, including some involved in proliferation. Corepressor degradation also likely 
contributes to tamoxifen resistance.
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Corepressors and breast cancer
The majority of breast cancer tumors express ERα. Drugs
that target ERα have been a mainstay of breast cancer
treatment for nearly 50 years, yet many of the signaling
pathways that underlie such treatments remain incom-
pletely understood. This especially pertains to the selec-
tive estrogen receptor modulator (SERM) tamoxifen,
which remains an important agent in the treatment of
ERα-positive breast cancer. Tamoxifen is the major drug
used for early stage and advanced premenopausal ERα-
positive breast cancer and for prevention of breast cancer
in both younger and older women at high risk for devel-
oping the disease. Tamoxifen recruits corepressors SMRT
and N-CoR to dimerized estrogen receptors [46]. Binding
of these corepressors to ERα results in repression of ERα-
target genes, including those involved in cell proliferation,
through modification of histones and concomitant chro-
matin remodeling to a more compact state. Thus, core-
pressor levels are critical for tamoxifen-mediated
transcriptional repression and its anti-proliferative activity
[47,48]. However, alterations in the balance between
coactivators and corepressors can switch tamoxifen from
an antagonist to an agonist of ERα-dependent gene
expression [49]. Imbalance in the coactivator to corepres-
sor ratio is hypothesized to be a major contributor to
tamoxifen resistance in breast cancer (Figure 2). Breast
cancer patients that are both ERα-positive and ErbB2-pos-
itive are resistant to tamoxifen therapy. Our data strongly
suggest that inhibition of Cdk2 and/or Pin1 in ERα-posi-
tive and ErbB2-positive breast cancer cells will enhance
the anti-tumor activity of tamoxifen.
ErbB2 has been shown to act upstream of both Cdk2 and
Pin1. ErbB2 activates the E2F family of transcription fac-
tors which in turn increase transcription of both Pin1 [50]
and Cyclins A and E [51], both of which are activating fac-
tors for Cdk2. Activation of Cdk2 has been implicated in
anti-estrogen (tamoxifen) resistance [52]. Pin1 overex-
pression is prevalent in many different cancers including
breast cancer [53] and there is strong correlation between
its overexpression and breast cancer in patients [53,54].
Furthermore, Pin1 has recently been shown to stabilize
ErbB2 [55], thus completing a positive feedback loop.
ErbB2 is also overexpressed in some ERα-negative breast
cancers and prostate cancers. Androgen receptor (AR) is
an essential component in androgen-dependent prostate
cancer. Similar to ERα, androgen receptor can employ
SMRT and N-CoR to repress target genes. Furthermore,
overexpression of SMRT or restoring the association of
SMRT with AR on AR target genes by MEK inhibitors cor-
relates with the ability of antiandrogens to inhibit pros-
tate cancer cell growth [56]. Therefore, identification of
SMRT as a downstream target of ErbB2 that plays a critical
role in transcriptional regulation will help develop thera-
peutic agents for ErbB2-positive cancer patients, such as
screening small molecule(s) that increase SMRT protein
levels.
Potential roles for corepressors in cell cycle 
regulation
While neither SMRT nor N-CoR have been assigned a
direct role in regulating the cell cycle, SMRT levels have
been reported to fluctuate during mitosis [4]. Knockdown
of both SMRT and N-CoR by siRNA increased cell prolif-
eration rates in MCF7 cells [57] while our data indicated
SMRT knockdown alone was sufficient to increase prolif-
eration rates in BT474 cells [45]. Furthermore, both Cdk2
and Pin1 are established cell cycle-regulating enzymes
[58,59].
Several recent reports have identified a novel role for
HDAC3 in cell cycle regulation. In terms of transcriptional
regulation, HDAC3 has been shown to repress several crit-
ical cell cycle regulators such as the E3 ubiquitin ligase
Skp2 [60,61] and several Cdk inhibitors [62]. In addition
to transcriptional repression, HDAC3 deacetylates H3
localized at centromeres [63] and facilitates Aurora B
recruitment to phosphorylate H3, a required histone
modification to proceed through mitosis [64]. HDAC3
has also been shown to localize to the mitotic spindle
[65], although its function there remains unknown. Since
SMRT is critical for HDAC3 deacetylase activity, we specu-
Corepressors and tamoxifen-resistant breastcancers Figure 2
Corepressors and tamoxifen-resistant breastcan-
cers. Estrogen receptors (ER) can interact with either coac-
tivators or corepressors. Tamoxifen, a common treatment 
for ERα-positive breast cancers, induces an ERα conforma-
tional change that favors recruitment of corepressors to 
repress proliferative genes controlled by ERα. However, 
some breast cancers show ERα recruitment of coactivators 
even in the presence of tamoxifen, thus resulting in activation 
of proliferative genes. Many of these tamoxifen-resistant 
breast cancers overexpress the oncogene ErbB2, which has 
been shown to increase coactivator levels and decrease 
corepressor levels, thus altering the delicate ratio between 
these critical factors.
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late that SMRT may also be important for these activities
and thus critical for normal cell cycle progression.
Both whole animal and targeted deletion of HDAC3 sug-
gest a role for this enzyme in cell cycle regulation. HDAC3
-/- MEFs (mouse embryonic fibroblasts) show delayed cell
cycling, higher levels of DNA damage and increased apop-
tosis [66]. Targeted deletion of HDAC3 in either heart
[67] or liver [68] resulted in organ hypertrophy that may
be attributed to increased proliferation. Together, HDACs
and their associated corepressor complexes have been
identified as potentially important targets in treating vari-
ous cancers [69], although further study is necessary to
elucidate the mechanisms underlying the roles of these
corepressors in cell cycle regulation.
Concluding remarks
Since the isolation of the transcriptional corepressors
SMRT and N-CoR more than ten years ago, the major
focus has been their respective roles in transcriptional reg-
ulation. These biochemical and molecular studies have
established how these two large platform proteins func-
tion in many cellular processes. In addition, recent animal
and cellular studies have further advanced our under-
standing of the physiological function and regulation of
SMRT and N-CoR. However, we believe that we are only
beginning to elucidate the complex regulatory network
and biological activity of these two proteins. As SMRT and
N-CoR play important roles in animal development,
homeostasis and are also associated with human diseases,
elucidation of the mechanisms and upstream signaling
controlling their activities is critical.
Several important avenues remain unexplored. For exam-
ple, if HDAC3 is a stable component of SMRT and N-CoR
corepressor complexes and a critical regulator of the cell
cycle, are SMRT or N-CoR also critical for HDAC3-medi-
ated cell cycle progression? Is SMRT or N-CoR regulated in
a cell cycle-dependent manner? How do SMRT and N-CoR
contribute to DNA damage repair and how do post-trans-
lational modifications control stability of these two core-
pressors? These questions warrant future investigation.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
KJS and HYK drafted the manuscript.
Acknowledgements
We would like to thank Drs. E. Reineke and D. Samols for critical com-
ments on the manuscript. H.Y. Kao is supported by Pardee Foundation, 
American Cancer Society, and NIH (DK078965).
References
1. Sonoda J, Pei L, Evans RM: Nuclear receptors: decoding meta-
bolic disease.  FEBS Lett 2008, 582(1):2-9.
2. Nagy L, Schwabe JW: Mechanism of the nuclear receptor
molecular switch.  Trends Biochem Sci 2004, 29(6):317-24.
3. Sande S, Privalsky ML: Identification of TRACs (T3 receptor-
associating cofactors), a family of cofactors that associate
with, and modulate the activity of, nuclear hormone recep-
tors.  Mol Endocrinol 1996, 10(7):813-25.
4. Park EJ, Schroen DJ, Yang M, Li H, Li L, Chen JD: SMRTe, a silenc-
ing mediator for retinoid and thyroid hormone receptors-
extended isoform that is more related to the nuclear recep-
tor corepressor.  Proc Natl Acad Sci USA 1999, 96(7):3519-24.
5. Ordentlich P, Downes M, Xie W, Genin A, Spinner NB, Evans RM:
Unique forms of human and mouse nuclear receptor core-
pressor SMRT.  Proc Natl Acad Sci USA 1999, 96(6):2639-44.
6. Chen JD, Evans RM: A transcriptional co-repressor that inter-
acts with nuclear hormone receptors.  Nature 1995,
377(6548):454-7.
7. Horlein AJ, Naar AM, Heinzel T, Torchia J, Gloss B, Kurokawa R,
Ryan A, Kamei Y, Soderstrom M, Glass CK, Rosenfeld MG: Ligand-
independent repression by the thyroid hormone receptor
mediated by a nuclear receptor co-repressor.  Nature 1995,
377(6548):397-404.
8. Privalsky ML: The role of corepressors in transcriptional regu-
lation by nuclear hormone receptors.  Annu Rev Physiol 2004,
66:315-60.
9. Goodson M, Jonas BA, Privalsky MA: Corepressors: custom tai-
loring and alterations while you wait.  Nucl Recept Signal 2005,
3:e003.
10. Guenther MG, Barak O, Lazar MA: The SMRT and N-CoR core-
pressors are activating cofactors for histone deacetylase 3.
Mol Cell Biol 2001, 21(18):6091-101.
11. Yu J, Li Y, Ishizuka T, Guenther MG, Lazar MA: A SANT motif in
the SMRT corepressor interprets the histone code and pro-
motes histone deacetylation.  Embo J 2003, 22(13):3403-10.
12. Zhang J, Kalkum M, Chait BT, Roeder RG: The N-CoR-HDAC3
nuclear receptor corepressor complex inhibits the JNK path-
way through the integral subunit GPS2.  Mol Cell 2002,
9(3):611-23.
13. Yoon HG, Chan DW, Huang ZQ, Li J, Fondell JD, Qin J, Wong J: Puri-
fication and functional characterization of the human N-CoR
complex: the roles of HDAC3, TBL1 and TBLR1.  Embo J 2003,
22(6):1336-46.
14. Li J, Wang J, Nawaz Z, Liu JM, Qin J, Wong J: Both corepressor pro-
teins SMRT and N-CoR exist in large protein complexes con-
taining HDAC3.  Embo J 2000, 19(16):4342-50.
15. Guenther MG, Lane WS, Fischle W, Verdin E, Lazar MA, Shiekhattar
R: A core SMRT corepressor complex containing HDAC3
and TBL1, a WD40-repeat protein linked to deafness.  Genes
Dev 2000, 14(9):1048-57.
16. Perissi V, Aggarwal A, Glass CK, Rose DW, Rosenfeld MG: A core-
pressor/coactivator  exchange complex required for tran-
scriptional activation by nuclear receptors and other
regulated transcription factors.  Cell 2004, 116(4):511-26.
17. Fischle W, Dequiedt F, Hendzel MJ, Guenther MG, Lazar MA, Voelter
W, Verdin E: Enzymatic activity associated with class II
HDACs is dependent on a multiprotein complex containing
HDAC3 and SMRT/N-CoR.  Mol Cell 2002, 9(1):45-57.
18. Fischle W, Dequiedt F, Fillion M, Hendzel MJ, Voelter W, Verdin E:
Human HDAC7 histone deacetylase activity is associated
with HDAC3 in vivo.  J Biol Chem 2001, 276(38):35826-35.
19. Huang EY, Zhang J, Miska EA, Guenther MG, Kouzarides T, Lazar MA:
Nuclear receptor corepressors partner with class II histone
deacetylases in a Sin3-independent repression pathway.
Genes Dev 2000, 14(1):45-54.
20. Kao HY, Downes M, Ordentlich P, Evans RM: Isolation of a novel
histone deacetylase reveals that class I and class II deacety-
lases promote SMRT-mediated repression.  Genes Dev 2000,
14(1):55-66.
21. Heinzel T, Lavinsky RM, Mullen TM, Soderstrom M, Laherty CD,
Torchia J, Yang WM, Brard G, Ngo SD, Davie JR, Seto E, Eisenman
RN, Rose DW, Glass CK, Rosenfeld MG: A complex containingCell Division 2009, 4:7 http://www.celldiv.com/content/4/1/7
Page 7 of 8
(page number not for citation purposes)
N-CoR, mSin3 and histone deacetylase mediates transcrip-
tional repression.  Nature 1997, 387(6628):43-8.
22. Alland L, Muhle R, Hou H Jr, Potes J, Chin L, Schreiber-Agus N,
DePinho RA: Role for N-CoR and histone deacetylase in Sin3-
mediated transcriptional repression.  Nature 1997,
387(6628):49-55.
23. Nagy L, Kao HY, Chakravarti D, Lin RJ, Hassig CA, Ayer DE, Sch-
reiber SL, Evans RM: Nuclear receptor repression mediated by
a complex containing SMRT, mSin3A, and histone deacety-
lase.  Cell 1997, 89(3):373-80.
24. Guenther MG, Yu J, Kao GD, Yen TJ, Lazar MA: Assembly of the
SMRT-histone deacetylase 3 repression complex requires
the TCP-1 ring complex.  Genes Dev 2002, 16(24):3130-5.
25. Johnson CA, White DA, Lavender JS, O'Neill LP, Turner BM: Human
class I histone deacetylase complexes show enhanced cata-
lytic activity in the presence of ATP and co-immunoprecipi-
tate with the ATP-dependent chaperone protein Hsp70.  J
Biol Chem 2002, 277(11):9590-7.
26. Vermeulen M, Carrozza MJ, Lasonder E, Workman JL, Logie C, Stun-
nenberg HG: In vitro targeting reveals intrinsic histone tail
specificity of the Sin3/histone deacetylase and N-CoR/SMRT
corepressor complexes.  Mol Cell Biol 2004, 24(6):2364-72.
27. Hartman HB, Yu J, Alenghat T, Ishizuka T, Lazar MA: The histone-
binding code of nuclear receptor co-repressors matches the
substrate specificity of histone deacetylase 3.  EMBO Rep 2005,
6(5):445-51.
28. Jepsen K, Solum D, Zhou T, McEvilly RJ, Kim HJ, Glass CK, Herman-
son O, Rosenfeld MG: SMRT-mediated repression of an H3K27
demethylase in progression from neural stem cell to neuron.
Nature 2007, 450(7168):415-419.
29. Jepsen K, Gleiberman AS, Shi C, Simon DI, Rosenfeld MG: Cooper-
ative regulation in development by SMRT and FOXP1.  Genes
Dev 2008, 22(6):740-5.
30. Jepsen K, Hermanson O, Onami TM, Gleiberman AS, Lunyak V,
McEvilly RJ, Kurokawa R, Kumar V, Liu F, Seto E, Hedrick SM, Mandel
G, Glass CK, Rose DW, Rosenfeld MG: Combinatorial roles of
the nuclear receptor corepressor in transcription and devel-
opment.  Cell 2000, 102(6):753-63.
31. Astapova I, Lee LJ, Morales C, Tauber S, Bilban M, Hollenberg AN:
The nuclear corepressor, NCoR, regulates thyroid hormone
action in vivo.  Proc Natl Acad Sci USA 2008, 105(49):19544-9.
32. Nofsinger RR, Li P, Hong SH, Jonker JW, Barish GD, Ying H, Cheng
SY, Leblanc M, Xu W, Pei L, Kang YJ, Nelson M, Downes M, Yu RT,
Olefsky JM, Lee CH, Evans RM: SMRT repression of nuclear
receptors controls the adipogenic set point and metabolic
homeostasis.  Proc Natl Acad Sci USA 2008, 105(50):20021-6.
33. Alenghat T, Meyers K, Mullican SE, Leitner K, Adeniji-Adele A, Avila
J, Bucan M, Ahima RS, Kaestner KH, Lazar MA: Nuclear receptor
corepressor and histone deacetylase 3 govern circadian met-
abolic physiology.  Nature 2008, 456(7224):997-1000.
34. Hoberg JE, Yeung F, Mayo MW: SMRT derepression by the Ikap-
paB kinase alpha: a prerequisite to NF-kappaB transcription
and survival.  Mol Cell 2004, 16(2):245-55.
35. Hoberg JE, Popko AE, Ramsey CS, Mayo MW: IkappaB kinase
alpha-mediated derepression of SMRT potentiates acetyla-
tion of RelA/p65 by p300.  Mol Cell Biol 2006, 26(2):457-71.
36. Zhou Y, Gross W, Hong SH, Privalsky ML: The SMRT corepressor
is a target of phosphorylation by protein kinase CK2 (casein
kinase II).  Mol Cell Biochem 2001, 220:1-2.
37. Hong SH, Wong CW, Privalsky ML: Signaling by tyrosine kinases
negatively regulates the interaction between transcription
factors and SMRT (silencing mediator of retinoic acid and
thyroid hormone receptor) corepressor.  Mol Endocrinol 1998,
12(8):1161-71.
38. Hong SH, Privalsky ML: The SMRT corepressor is regulated by
a MEK-1 kinase pathway: inhibition of corepressor function
is associated with SMRT phosphorylation and nuclear
export.  Mol Cell Biol 2000, 20(17):6612-25.
39. Jonas BA, Privalsky ML: SMRT and N-CoR corepressors are reg-
ulated by distinct kinase signaling pathways.  J Biol Chem 2004,
279(52):54676-86.
40. McKenzie GJ, Stevenson P, Ward G, Papadia S, Bading H, Chawla S,
Privalsky M, Hardingham GE: Nuclear Ca2+ and CaM kinase IV
specify hormonal- and Notch-responsiveness.  J Neurochem
2005, 93(1):171-85.
41. Yu J, Palmer C, Alenghat T, Li Y, Kao G, Lazar MA: The corepressor
silencing mediator for retinoid and thyroid hormone recep-
tor facilitates cellular recovery from DNA double-strand
breaks.  Cancer Res 2006, 66(18):9316-22.
42. Jeyakumar M, Liu XF, Erdjument-Bromage H, Tempst P, Bagchi MK:
Phosphorylation of thyroid hormone receptor-associated
nuclear receptor corepressor holocomplex by the DNA-
dependent protein kinase enhances its histone deacetylase
activity.  J Biol Chem 2007, 282(13):9312-22.
43. Zhang J, Guenther MG, Carthew RW, Lazar MA: Proteasomal reg-
ulation of nuclear receptor corepressor-mediated repres-
sion.  Genes Dev 1998, 12(12):1775-80.
44. Frasor J, Danes JM, Funk CC, Katzenellenbogen BS: Estrogen down-
regulation of the corepressor N-CoR: mechanism and impli-
cations for estrogen derepression of N-CoR-regulated genes.
Proc Natl Acad Sci USA 2005, 102(37):13153-7.
45. Stanya KJ, Liu Y, Means AR, Kao HY: Cdk2 and Pin1 negatively
regulate the transcriptional corepressor SMRT.  J Cell Biol
2008, 183(1):49-61.
46. Lavinsky RM, Jepsen K, Heinzel T, Torchia J, Mullen TM, Schiff R, Del-
Rio AL, Ricote M, Ngo S, Gemsch J, Hilsenbeck SG, Osborne CK,
Glass CK, Rosenfeld MG, Rose DW: Diverse signaling pathways
modulate nuclear receptor recruitment of N-CoR and
SMRT complexes.  Proc Natl Acad Sci USA 1998, 95(6):2920-5.
47. Graham JD, Bain DL, Richer JK, Jackson TA, Tung L, Horwitz KB:
Nuclear receptor conformation, coregulators, and
tamoxifen-resistant breast cancer.  Steroids.   2000, 65(10-
11):579-584.
48. Graham JD, Bain DL, Richer JK, Jackson TA, Tung L, Horwitz KB:
Thoughts on tamoxifen resistant breast cancer. Are coregu-
lators the answer or just a red herring?  J Steroid Biochem Mol Biol
2000, 74(5):255-9.
49. Smith CL, Nawaz Z, O'Malley BW: Coactivator and corepressor
regulation of the agonist/antagonist activity of the mixed
antiestrogen, 4-hydroxytamoxifen.  Mol Endocrinol 1997,
11(6):657-66.
50. Ryo A, Liou YC, Wulf G, Nakamura M, Lee SW, Lu KP: PIN1 is an
E2F target gene essential for Neu/Ras-induced transforma-
tion of mammary epithelial cells.  Mol Cell Biol 2002,
22(15):5281-95.
51. Neve RM, Sutterluty H, Pullen N, Lane HA, Daly JM, Krek W, Hynes
NE: Effects of oncogenic ErbB2 on G1 cell cycle regulators in
breast tumour cells.  Oncogene 2000, 19(13):1647-56.
52. Varma H, Skildum AJ, Conrad SE: Functional ablation of pRb acti-
vates Cdk2 and causes antiestrogen resistance in human
breast cancer cells.  PLoS ONE 2007, 2(12):e1256.
53. Bao L, Kimzey A, Sauter G, Sowadski JM, KP Lu, Wang DG: Preva-
lent overexpression of prolyl isomerase Pin1 in human can-
cers.  Am J Pathol 2004, 164(5):1727-37.
54. Suizu F, Ryo A, Wulf G, Lim J, Lu KP: Pin1 regulates centrosome
duplication, and its overexpression induces centrosome
amplification, chromosome instability, and oncogenesis.  Mol
Cell Biol 2006, 26(4):1463-79.
55. Lam PB, Burga LN, Wu BP, Hofstatter EW, Lu KP, Wulf GM: Prolyl
isomerase Pin1 is highly expressed in Her2-positive breast
cancer and regulates erbB2 protein stability.  Mol Cancer 2008,
7:91.
56. Eisold M, Asim M, Eskelinen H, Linke T, Baniahmad A: Inhibition of
MAPK-signaling pathway promotes the interactionof the
corepressor SMRT with the human androgen receptor and
mediatesrepression of prostate cancer cells growth in the
presence ofantiandrogens.  J Mol Endocrinol 2009, 42(5):429-35.
Epub 2009 Feb 17
57. Keeton EK, Brown M: Cell cycle progression stimulated by
tamoxifen-bound estrogen receptor-alpha and promoter-
specific effects in breast cancer cells deficient in N-CoR and
SMRT.  Mol Endocrinol 2005, 19(6):1543-54.
58. Yeh ES, Means AR: PIN1, the cell cycle and cancer.  Nat Rev Can-
cer 2007, 7(5):381-8.
59. Malumbres M, Barbacid M: Cell cycle kinases in cancer.  Curr Opin
Genet Dev 2007, 17(1):60-5.
60. Schneider G, Reichert M, Saur D, Hamacher R, Fritsch R, Schmid RM:
HDAC3 is linked to cell cycle machinery in MiaPaCa2 cells
by regulating transcription of skp2.  Cell Prolif 2007,
40(4):522-31.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Cell Division 2009, 4:7 http://www.celldiv.com/content/4/1/7
Page 8 of 8
(page number not for citation purposes)
61. Zhang Y, Tuzova M, Xiao ZX, Cruikshank WW, Center DM: Pro-IL-
16 recruits histone deacetylase 3 to the Skp2 core promoter
through interaction with transcription factor GABP.  J Immu-
nol 2008, 180(1):402-8.
62. Huang W, Tan D, Wang X, Han S, Tan J, Zhao Y, Lu J, Huang B: His-
tone deacetylase 3 represses p15(INK4b) and p21(WAF1/
cip1) transcription by interacting with Sp1.  Biochem Biophys Res
Commun 2006, 339(1):165-71.
63. Eot-Houllier G, Fulcrand G, Watanabe Y, Magnaghi-Jaulin L, Jaulin C:
Histone deacetylase 3 is required for centromeric H3K4
deacetylation and sister chromatid cohesion.  Genes Dev 2008,
22(19):2639-44.
64. Li Y, Kao GD, Garcia BA, Shabanowitz J, Hunt DF, Qin J, Phelan C,
Lazar MA: A novel histone deacetylase pathway regulates
mitosis by modulating Aurora B kinase activity.  Genes Dev
2006, 20(18):2566-79.
65. Ishii S, Kurasawa Y, Wong J, Yu-Lee LY: Histone deacetylase 3
localizes to the mitotic spindle and is required for kineto-
chore-microtubule attachment.  Proc Natl Acad Sci USA 2008,
105(11):4179-84.
66. Bhaskara S, Chyla BJ, Amann JM, Knutson SK, Cortez D, Sun ZW,
Hiebert SW: Deletion of histone deacetylase 3 reveals critical
roles in S phase progression and DNA damage control.  Mol
Cell 2008, 30(1):61-72.
67. Montgomery RL, Potthoff MJ, Haberland M, Qi X, Matsuzaki S, Hum-
phries KM, Richardson JA, Bassel-Duby R, Olson EN: Maintenance
of cardiac energy metabolism by histone deacetylase 3 in
mice.  J Clin Invest 2008, 118(11):3588-97.
68. Knutson SK, Chyla BJ, Amann JM, Bhaskara S, Huppert SS, Hiebert
SW: Liver-specific deletion of histone deacetylase 3 disrupts
metabolic transcriptional networks.  Embo J 2008,
27(7):1017-28.
69. Yang XJ, Seto E: The Rpd3/Hda1 family of lysine deacetylases:
from bacteria and yeast to mice and men.  Nat Rev Mol Cell Biol
2008, 9(3):206-18.